Are Options Traders Anticipating a Significant Shift in Artivion Stock?

Written by Emily J. Thompson, Senior Investment Analyst

AORT-2.11%

Source: NASDAQ.COM

Updated: Sep 25 2025

0mins

Source: NASDAQ.COM

Artivion Stock and Options Market: Artivion, Inc. (AORT) is experiencing high implied volatility in its options market, particularly with the Oct 17, 2025 $30.00 Put, indicating that investors expect significant price movement in the near future.
Analyst Sentiment and Earnings Estimates: Currently rated as a Zacks Rank #3 (Hold), Artivion has seen no upward revisions in earnings estimates over the last 60 days, with a consensus estimate decrease from 15 cents to 14 cents per share, suggesting cautious sentiment among analysts.
AI Investment Opportunities: The article discusses the potential for significant wealth creation in the next phase of AI, highlighting that early investors in companies like Nvidia have seen substantial gains, but warns that the rapid growth of the first wave of AI stocks may soon stabilize.
Zacks Investment Research Recommendations: Zacks offers insights into emerging AI companies poised for growth and provides a report on the "AI Boom 2.0," along with recommendations for stocks to consider in the coming month.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like AORT with instant alerts to capture every critical market movement.

Sign up for free to build your custom watchlist and receive professional-grade stock notifications.

AORT

$40.42+Infinity%1D

Analyst Views on AORT

Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Analyst Rating

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 41.290

Low

40.00

Averages

51.71

High

58.00

Current: 41.290

Low

40.00

Averages

51.71

High

58.00

Ladenburg

Jeffrey Cohen

Neutral

maintain

$38 -> $40

2025-11-07

Reason

Ladenburg

Jeffrey Cohen

Price Target

$38 -> $40

AI Analysis

2025-11-07

maintain

Neutral

Reason

Ladenburg analyst Jeffrey Cohen raised the firm's price target on Artivion to $40 from $38 and keeps a Neutral rating on the shares.

Oppenheimer

Outperform

maintain

$40 -> $50

2025-11-07

Reason

Oppenheimer

Price Target

$40 -> $50

2025-11-07

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Artivion to $50 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 revenue of $113.4M, +16% year-over-year, above its/consensus estimate of $112M/$110M. FY25 revenue guidance was raised, now $439M-$445M, and management remains confident about double-digit top-line growth.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AORT

Unlock Now

About AORT

Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons’ challenges in treating patients with aortic diseases. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. It has four major product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Its Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. Its Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include its BioGlue Surgical Adhesive products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.